Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortés(Villa Maria Hospital), Chris Twelves(University of Leeds), Seth Seegobin(Eisai (Japan)), Joanne L. Blum(Texas Oncology), Katarína Petráková(Masaryk Memorial Cancer Institute), T. Delozier(Mount Vernon Hospital), Véronique Dièras(Institut Curie), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Corina E. Dutcus(Eisai (United States)), Vladimir Vladimirov(Pyatigorsk Oncology Center), Joyce O’Shaughnessy(Baylor University Medical Center), P. Chollet(Centre Jean Perrin), Philippe Bougnoux(Centre Hospitalier Universitaire de Tours), David Loesch(Caris Life Sciences (United States)), Alexey Manikas(City Clinical Oncology Center), Nicole Meneses(Eisai (United States)), J. Wanders(Eisai (United Kingdom)), Denis Mir(Eisai (Japan)), Han Koh(Universitair Ziekenhuis Leuven), Fátima Cardoso(Breast Cancer Alliance)
Cited by 1,094
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k